BioCentury | Jan 20, 2021
Product Development

Trucode reboots as Vera with Abingworth-led $80M series C, disease-modifying therapy for orphan kidney disease

Sixteen months after it emerged from stealth, Trucode has moved on from gene editing and relaunched as Vera with an Abingworth-led $80 million series C round to build an in-licensed portfolio of autoimmune assets. First up for the...
BioCentury | May 21, 2020
Product Development

With AZ deal, Operation Warp Speed takes first step to train guns on coronavirus

...population are challenges that only the military is equipped to meet. In addition, its role vis-a-vis...
BioCentury | Mar 28, 2019
Product Development

Striking a cord for microbiome regulation with a path for FMTs

...be efficacious in certain situations, the data on the efficacy of these products, vis à vis...
BioCentury | Jul 13, 2018
Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said on July 11. The deal gives Otsuka a pipeline based on Visterra's Hierotope...
BioCentury | Jul 11, 2018
Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said Wednesday. The deal gives Otsuka a pipeline based on Visterra's Hierotope platform, which...
BioCentury | May 10, 2018
Emerging Company Profile

Abac’s precision platform

Abac Therapeutics S.A. is taking a precision approach to treat bacterial infections that could avoid the development of drug resistance that plagues broad-spectrum antibiotics. The company’s PasNas platform uses phenotypic and in vitro assays to...
BioCentury | Mar 30, 2018
Finance

Bug money

Despite the tremendous public health need and the introduction of regulatory incentives including expedited review and market exclusivity, venture investing in antibiotics remains modest and focused primarily on clinical assets seeking to improve on known...
BioCentury | Feb 23, 2018
Clinical News

Visterra reports preclinical data for dengue fever candidate

Visterra Inc. (Cambridge, Mass.) reported preclinical data from mouse models of primary and secondary dengue fever infection showing that VIS513 significantly reduced viral titers vs. controls and protected mice from lethal infections. Data were published...
BioCentury | Oct 28, 2017
Strategy

Biogen doubles down

...de-coupled in terms of discussion,” Vounatsos added. “There is no master plan of opting in vis-à-vis...
BioCentury | Oct 20, 2017
Company News

Vir unveils series of deals, additional funding

On Oct. 18, Vir Biotechnology Inc. (San Francisco, Calif.) revealed a crop of new deals and said it has raised more than $500 million to date. CEO George Scangos told BioCentury the company's current round...
Items per page:
1 - 10 of 44
BioCentury | Jan 20, 2021
Product Development

Trucode reboots as Vera with Abingworth-led $80M series C, disease-modifying therapy for orphan kidney disease

Sixteen months after it emerged from stealth, Trucode has moved on from gene editing and relaunched as Vera with an Abingworth-led $80 million series C round to build an in-licensed portfolio of autoimmune assets. First up for the...
BioCentury | May 21, 2020
Product Development

With AZ deal, Operation Warp Speed takes first step to train guns on coronavirus

...population are challenges that only the military is equipped to meet. In addition, its role vis-a-vis...
BioCentury | Mar 28, 2019
Product Development

Striking a cord for microbiome regulation with a path for FMTs

...be efficacious in certain situations, the data on the efficacy of these products, vis à vis...
BioCentury | Jul 13, 2018
Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said on July 11. The deal gives Otsuka a pipeline based on Visterra's Hierotope...
BioCentury | Jul 11, 2018
Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said Wednesday. The deal gives Otsuka a pipeline based on Visterra's Hierotope platform, which...
BioCentury | May 10, 2018
Emerging Company Profile

Abac’s precision platform

Abac Therapeutics S.A. is taking a precision approach to treat bacterial infections that could avoid the development of drug resistance that plagues broad-spectrum antibiotics. The company’s PasNas platform uses phenotypic and in vitro assays to...
BioCentury | Mar 30, 2018
Finance

Bug money

Despite the tremendous public health need and the introduction of regulatory incentives including expedited review and market exclusivity, venture investing in antibiotics remains modest and focused primarily on clinical assets seeking to improve on known...
BioCentury | Feb 23, 2018
Clinical News

Visterra reports preclinical data for dengue fever candidate

Visterra Inc. (Cambridge, Mass.) reported preclinical data from mouse models of primary and secondary dengue fever infection showing that VIS513 significantly reduced viral titers vs. controls and protected mice from lethal infections. Data were published...
BioCentury | Oct 28, 2017
Strategy

Biogen doubles down

...de-coupled in terms of discussion,” Vounatsos added. “There is no master plan of opting in vis-à-vis...
BioCentury | Oct 20, 2017
Company News

Vir unveils series of deals, additional funding

On Oct. 18, Vir Biotechnology Inc. (San Francisco, Calif.) revealed a crop of new deals and said it has raised more than $500 million to date. CEO George Scangos told BioCentury the company's current round...
Items per page:
1 - 10 of 44